IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma

Pediatric Research

Volumn 63, Issue 3, 2008, Pages 263-267

  Picard, Arnaud ^b,c,d   Boscolo, Elisa ^a   Khan, Zia A ^a   Bartch, Tatianna C ^a   Mulliken, John B ^a   Vazquez, Marie Paule ^b,c,d   Bischoff, Joyce ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MESSENGER RNA; SOMATOMEDIN B; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE TRANSPORT; HEMANGIOMATOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RELEASE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TISSUE SECTION; TUMOR LOCALIZATION;

ADULT; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOMA; HUMANS; INFANT; INFANT, NEWBORN; INSULIN-LIKE GROWTH FACTOR II; NEOPLASM REGRESSION, SPONTANEOUS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 39749184770     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/PDR.0b013e318163a243     Document Type: Article

References (14)

1. Enjolras O, Mulliken JB 1998 Vascular tumors and vascular malformations: new issues. Adv Dermatol 13:375-423
2. Boon LM, Enjolras O, Mulliken JB 1996 Congenital hemangioma: evidence of accelerated involution. J Pediatr 128:329-335
3. Berenguer B, Mulliken JB, Enjolras O, Boon LM, Wassef M, Josset P, Burrows PE, Perez-Atayde AR, Kozakewich HP 2003 Rapidly involuting congenital hemangioma: clinical and histopathologic features. Pediatr Dev Pathol 6:495-510
4. Enjolras O, Mulliken JB, Boon LM, Wassef M, Kozakewich HP, Burrows PE 2001 Noninvoluting congenital hemangioma: a rare cutaneous vascular anomaly. Plast Reconstr Surg 107:1647-1654
5. Mulliken JB, Enjolras O 2004 Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol 50:875-882
6. North PE, Waner M, Mizeracki A, Mihm MC Jr 2000 GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31:11-22
7. Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M 2002 Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 99:7455-7460
8. Yu Y, Wylie-Sears J, Boscolo E, Mulliken JB, Bischoff J 2004 Genomic imprinting of IGF2 is maintained in infantile hemangioma despite its high level of expression. Mol Med 10:117-123
9. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A 2001 Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276:9519-9525
10. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL 1999 Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59:3915-3918
11. Maru Y, Yamaguchi S, Shibuya M 1998 Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene 16:2585-2595
12. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M 1998 Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745
13. Gluzman-Poltorak Z, Cohen T, Herzog Y, Neufeld G 2000 Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J Biol Chem 275:18040-18045
14. Ginzinger DG 2002 Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol 30:503-512